StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-18 | $4.14 | $3.65 | -11.90% | 0.1M |
| 05-19 | $3.61 | $3.29 | -8.86% | 0.1M |
| 05-20 | $3.20 | $2.83 | -11.56% | 0.2M |
| 05-21 | $2.85 | $2.63 | -7.72% | 0.1M |
| 05-22 | $2.63 | $2.57 | -2.28% | 0.1M |
Intelligent Bio Solutions Inc is a life sciences company developing non-invasive, real-time monitoring and diagnostic tests for patients and their primary health practitioners. Its Biosensor Platform is developing and launching diagnostic tests urgently needed to help people living with chronic diseases. It also engages in the advancement of portable drug abuse testing through the analysis of fingerprint sweat. The test is non-invasive, hygienic, and fast, and screens for recent use of opioids, cocaine, methamphetamines, benzodiazepines, and marijuana. The company operates through new reportable segments: United Kingdom; Asia Pacific (APAC); Americas; and Rest of World, of which United Kingdom derives maximum revenue.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Q4 2025 2025-12-31 | Q3 2025 2025-09-30 | Annual 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $3.07M | $2.01M | $1.11M | $3.05M |
Operating Income | $-8.64M | $-5.64M | $-3.00M | $-10.64M |
Net Income | $-8.52M | $-5.66M | $-2.98M | $-10.57M |
EPS (Diluted) | $-7.54 | $-6.27 | $-0.35 | $-2.00 |
Total Assets | $14.86M | $17.65M | $10.04M | $8.25M |
Total Liabilities | $6.11M | $6.76M | $6.61M | $5.44M |
Cash & Equivalents | $6.86M | $740.37K | $1.66M | $1.02M |
Free Cash Flow OCF − CapEx | $-8.87M | $-4.55M | $-2.92M | $-9.91M |
Shares Outstanding | 2.00M | 1.24M | 9.10M | 732.33K |
No sell-side coverage available for INBS yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.